公开(公告)号：US20100310534A1

公开(公告)日：2010-12-09

申请号：US12679696

申请日：2008-09-15

Applicant: Kfir Oved ,  Eran Eden ,  Martin Akerman ,  Roy Noy ,  Michal Besser ,  Yoram Reiter

Inventor： Kfir Oved ,  Eran Eden ,  Martin Akerman ,  Roy Noy ,  Michal Besser ,  Yoram Reiter

IPC: A61K35/12 ,  G01N33/50 ,  A61P35/00

CPC classification number: G01N33/57484 ,  G01N33/505 ,  G01N2800/52

Abstract: A method of determining responsiveness to cancer treatment is disclosed. The method comprises analyzing a frequency of tumor infiltrating lymphocytes (TILs) having a CD8+CD28−CD152− signature in a sample of the subject, wherein a frequency of TILs having the CD8+CD28−CD152− signature above a predetermined level is indicative of a positive responsiveness to cancer treatment. Other signatures reflecting responsiveness to cancer treatment are also disclosed. In addition, methods of treating cancer based on these signatures are also disclosed.

Abstract translation: 公开了一种确定对癌症治疗的反应性的方法。 该方法包括分析受试者样本中具有CD8 + CD28-CD152特征的肿瘤浸润性淋巴细胞（TIL）的频率，其中具有高于预定水平的CD8 + CD28-CD152特征的TIL频率指示 对癌症治疗的积极反应。 还公开了反映对癌症治疗反应的其他签名。 此外，还公开了基于这些标记治疗癌症的方法。

公开(公告)号：US20050255101A1

公开(公告)日：2005-11-17

申请号：US10073301

申请日：2002-02-13

Applicant: Yoram Reiter ,  Galit Denkberg

Inventor： Yoram Reiter ,  Galit Denkberg

IPC: G01N33/53 ,  A61K39/395 ,  A61K47/48 ,  A61P31/12 ,  A61P37/02 ,  C07K7/06 ,  C07K16/18 ,  C07K16/28 ,  C12N15/09 ,  C12P21/02 ,  C12P21/08 ,  C12Q1/02 ,  G01N33/569 ,  G01N33/574 ,  C07K16/30

CPC classification number: C07K16/2833 ,  A61K47/6849 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2319/00

Abstract: An isolated molecule which comprises an antibody specifically bindable with a binding affinity below 20 nanomolar, preferably below 10 nanomolar, to a human major histocompatibility complex (MHC) class I being complexed with a HLA-restricted antigen and optionally further comprises an identifiable or therapeutic moiety conjugated to the antibody.

Abstract translation: 一种分离的分子，其包含与HLA限制性抗原复合的人类主要组织相容性复合物（MHC）I类具有低于20纳摩尔，优选低于10纳摩尔的结合亲和力特异性结合的抗体，并且任选地还包含可识别或治疗性部分 与抗体缀合。

公开(公告)号：US20050152912A1

公开(公告)日：2005-07-14

申请号：US11074803

申请日：2005-03-09

Applicant: Yoram Reiter ,  Cyril Cohen

Inventor： Yoram Reiter ,  Cyril Cohen

IPC: A61K39/00 ,  C07K16/22 ,  A61K39/395 ,  A61K39/42 ,  C07H21/04 ,  A61K39/385 ,  C07K16/08

CPC classification number: A61K39/00 ,  A61K39/0005 ,  A61K39/21 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/22 ,  C07K16/28 ,  C07K2317/73

Abstract: A composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen is disclosed.

Abstract translation: 公开了一种包含抗体或抗体片段的物质组合物，其包括能够特异性结合由人抗原呈递分子组成的复合物的抗原呈递部分和源自病原体的抗原的抗原结合区域。

公开(公告)号：US06423513B1

公开(公告)日：2002-07-23

申请号：US09479479

申请日：2000-01-10

Applicant: David J. Fitzgerald ,  Yoram Reiter ,  Ira Pastan

Inventor： David J. Fitzgerald ,  Yoram Reiter ,  Ira Pastan

IPC: C12P2104

CPC classification number: C07K14/21 ,  A61K38/00 ,  A61K47/6829 ,  C07K16/3069 ,  C07K2319/00

Abstract: This invention provides protease-activatable Pseudomonas exotoxin A-like (“PE-like”) proproteins. The proproteins comprise (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a modified PE translocation domain comprising an amino acid sequence sufficiently homologous to domain II of PE to effect translocation to a cell cytosol upon proteolytic cleavage, wherein the translocation domain comprises a cysteine-cysteine loop that comprises a protease activatable sequence cleavable by a protease and wherein the cysteine-cysteine loop is substantially un-activatable by furin; (3) optionally, a PE Ib-like domain comprising an amino acid sequence up to 1500 amino acids; (4) a cytotoxicity domain comprising an amino acid sequence substantially homologous to domain m of PE, the cytotoxicity domain having ADP-ribosylating activity; and (5) an endoplasmic reticulum (“ER”) retention sequence. The invention also provides methods of using these proproteins for killing target cells.

Abstract translation: 本发明提供蛋白酶活化的假单胞菌外毒素A样（“PE样”）前蛋白。 所述蛋白质包含（1）结合细胞表面受体的10至1500个氨基酸的细胞识别结构域; （2）修饰的PE易位结构域，其包含与PE的结构域II充分同源的氨基酸序列，以在蛋白水解切割时实现对细胞溶质的移位，其中所述易位结构域包含半胱氨酸 - 半胱氨酸环，其包含可被 蛋白酶，其中半胱氨酸 - 半胱氨酸环基因不被弗林蛋白酶激活; （3）任选地，包含至多1500个氨基酸的氨基酸序列的PE 1b样结构域; （4）细胞毒性结构域，其包含与PE的结构域m基本同源的氨基酸序列，细胞毒性结构域具有ADP-核糖基化活性; 和（5）内质网（“ER”）保留序列。 本发明还提供了使用这些蛋白质杀死靶细胞的方法。